Testing a new injection treatment for early lupus disease

Plain-English translation of NCT06411249 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.

What is this trial?

This is a 3-year study testing belimumab, an injectable medication designed to help people with early systemic lupus erythematosus (SLE)—an autoimmune disease where the body attacks its own tissues. Researchers want to understand how well and how safely this medication works for people whose lupus remains active even while taking standard first-line treatments. All participants will receive the medication to see how it affects their symptoms and disease activity over time.

Many people with early lupus continue to experience active disease even after starting standard treatments. This study exists to find out whether this medication can help control lupus better and reduce flares, particularly for patients in the early stages of the disease.

Do you qualify?

You likely qualify if…

you have been diagnosed with systemic lupus erythematosus within the past 2 years
you have positive autoantibody blood test results confirming lupus (either a high ANA level or anti-dsDNA antibodies)
your lupus is currently active despite taking standard first-line lupus medications
you have no permanent organ damage from lupus at the time of screening
you are willing and able to give informed consent and follow the study plan for 3 years

You likely don't qualify if…

you have had any cancer in the past 5 years (except for non-melanoma skin cancers that have been removed)
you have a serious active infection or have recently been treated with strong antibiotics (within 60 days)
you have untreated tuberculosis or are taking medication to suppress a chronic infection
you have had an organ transplant or stem cell transplant
you are pregnant, breastfeeding, or not using effective contraception (if applicable)

What participation looks like

You will receive the medication as an injection under your skin, with visits to the clinic throughout the 3-year study period. Researchers will monitor your lupus symptoms, disease activity, and any side effects through regular check-ups and blood tests. Your participation involves following the injection schedule, attending scheduled appointments, and reporting any changes in your symptoms or health to the study team.

AI-generated summary from trial data · Jun 5, 2026 · Not medical advice

Trial locations(114 sites)

United States

GSK Investigational Site, Anniston, Alabama

GSK Investigational Site, Flagstaff, Arizona

GSK Investigational Site, Mesa, Arizona

GSK Investigational Site, Tucson, Arizona

GSK Investigational Site, Covina, California